Is Abrilada in shortage in 2026? Get the latest update on Abrilada availability, why it's hard to find, current pricing, and how to get your prescription filled.
If you've had trouble finding Abrilada (Adalimumab-afzb) at your pharmacy recently, you might be wondering: is there a shortage? The short answer is no — Abrilada is not listed on the FDA's official drug shortage database as of early 2026. But that doesn't mean it's easy to find.
Many patients report difficulty getting their Abrilada prescriptions filled, even without a formal shortage. The reasons have more to do with how biologic medications are distributed and how insurance companies manage their formularies than with actual manufacturing problems.
Let's break down what's really going on and what you can do about it.
Yes, for many patients it is. Even though Pfizer is manufacturing Abrilada and supply appears stable, several factors make it harder to locate than a typical prescription:
For a detailed look at why this happens, read our article on why Abrilada is so hard to find in 2026.
The story of Abrilada's availability is tied to the broader adalimumab biosimilar landscape. Here's the timeline:
Abrilada was first approved by the FDA on November 15, 2019, as a biosimilar to Humira. However, due to patent settlements between Pfizer and AbbVie (Humira's manufacturer), Abrilada didn't launch in the U.S. market right away.
In 2023, multiple adalimumab biosimilars entered the U.S. market nearly simultaneously — a historic event in the biosimilar space. Abrilada launched in late 2023 and received its interchangeable designation in October 2023, meaning pharmacists could substitute it for Humira automatically.
However, the flood of biosimilars all entering the market at once created confusion. Insurance companies, pharmacy benefit managers (PBMs), and pharmacies had to decide which products to stock and cover.
Over 2024 and 2025, the market began to sort itself out. Some biosimilars gained preferred formulary positions with major PBMs, while others — including Abrilada in some cases — were less favored on certain plans. Pfizer positioned Abrilada aggressively on price, offering a wholesale list price approximately 60% below Humira, but formulary decisions aren't always based solely on price.
In 2026, Abrilada is available and being manufactured, but your ability to access it depends heavily on your insurance plan, your specialty pharmacy network, and your geographic location.
Cost is a major factor for patients on biologic medications. Here's what Abrilada costs in 2026:
For uninsured or underinsured patients, Pfizer offers a Patient Assistance Program that may provide Abrilada at no cost. Learn more in our guide to saving money on Abrilada.
The adalimumab biosimilar market continues to evolve. Some recent developments that may affect Abrilada patients:
Here's your action plan if you need Abrilada:
For more tips, read our guide on how to find Abrilada in stock near you.
Abrilada is not in a formal shortage, but that doesn't mean it's sitting on every pharmacy shelf waiting for you. The specialty pharmacy model, insurance formulary decisions, and a crowded biosimilar market all create real barriers for patients.
The most important thing you can do is plan ahead. Use tools like Medfinder, take advantage of Pfizer's support programs, and stay in close communication with your doctor and pharmacy. You have options — and you deserve access to the treatment that works for you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
